Creo Medical Group PLC
BST:1RC Stock Report
Creo Medical Group Balance Sheet Health
Financial Health criteria checks 5/6 Creo Medical Group has a total shareholder equity of £47.4M and total debt of £14.2M, which brings its debt-to-equity ratio to 30%. Its total assets and total liabilities are £69.3M and £21.9M respectively.
Key information
30.0%
Debt to equity ratio
Interest coverage ratio n/a Cash UK£9.80m Equity UK£47.40m Total liabilities UK£21.90m Total assets UK£69.30m
Recent financial health updates
Show all updates
New minor risk - Shareholder dilution Oct 27
Chairman recently bought €840k worth of stock Oct 25
New minor risk - Market cap size Oct 15
New minor risk - Shareholder dilution Oct 02
First half 2024 earnings released: UK£0.034 loss per share (vs UK£0.044 loss in 1H 2023) Oct 02
No longer forecast to breakeven Oct 01
New minor risk - Share price stability Sep 28 Micro-Tech (NL) International B.V. entered into a binding agreement to acquire 51% stake in Creo Medical, S.L.U. from Creo Medical Group PLC (AIM:CREO) for €36.7 million. Sep 20
New major risk - Financial position Sep 18
Creo Medical Group PLC, Annual General Meeting, Jun 26, 2024 Jun 02
Full year 2023 earnings released: UK£0.07 loss per share (vs UK£0.15 loss in FY 2022) May 16 Creo Medical Group plc Announces Board Changes May 15
Forecast to breakeven in 2026 May 07
New minor risk - Financial data availability May 03
Creo Medical Group PLC to Report Fiscal Year 2023 Results on May 15, 2024 Apr 26
New minor risk - Profitability Mar 11
Creo Medical Group plc Announces Microwave Lung Ablation Update Mar 01
Creo Medical Group plc Announces Continued Progress on the Phased Market Release of Its Latest Device, Speedboat® UltraSlim Feb 01
Forecast to breakeven in 2026 Dec 31
Creo Medical Group plc Announces First Use of Speedboat UltraSlim in the USA Dec 15
Creo Medical Group PLC Announces the Initiation of Its Commercial Launch of Speedboat Ultraslim Dec 13
New minor risk - Share price stability Dec 09
Creo Medical Group plc Receives 510(K) Clearance from the Us Food & Drug Administration for Its Speedboat Ultraslim Device Nov 02
Creo Medical Group plc Announces EU Launch Accelerated by 18 Months Eu Regulatory Pathway for Launch Early 2024 Oct 26
First half 2023 earnings released: UK£0.044 loss per share (vs UK£0.074 loss in 1H 2022) Sep 17
Creo Medical Group PLC to Report First Half, 2023 Results on Sep 12, 2023 Sep 05
New major risk - Share price stability Jun 29
Creo Medical Group PLC, Annual General Meeting, Jun 27, 2023 May 27
Creo Medical Group plc Announces First In-Human Milestone Reaches for Microblate Flex as Part of Lung Tissue Ablation Clinical Study May 23
Full year 2022 earnings released: UK£0.15 loss per share (vs UK£0.15 loss in FY 2021) Apr 27
Key Executive recently bought €612k worth of stock Mar 15
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 18 Creo Medical Group PLC has completed a Follow-on Equity Offering in the amount of £28.5 million. Feb 17
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 16
Less than half of directors are independent Nov 16
Creo Medical Limited, Annual General Meeting, Jun 28, 2022 Jun 29
Key Executive recently bought €55k worth of stock May 29
Creo Medical Limited to Report Fiscal Year 2021 Results on May 23, 2022 May 17
Less than half of directors are independent Apr 27
Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £5.06601 million. Sep 08
Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £31.250001 million. Aug 14
New 90-day high: €2.48 Feb 18
New 90-day high: €2.34 Jan 26
Creo Medical Group plc Receives US FDA clearance for MicroBlate™ Flex device Jan 08
New 90-day high: €2.10 Jan 07
New 90-day high: €2.06 Dec 11
New 90-day high: €1.94 Nov 24
New 90-day low: €1.47 Oct 30
New 90-day low: €1.70 Oct 13
First half earnings released Sep 29
New 90-day low - €1.78 Sep 09
Financial Position Analysis
Short Term Liabilities: 1RC's short term assets (£32.1M) exceed its short term liabilities (£9.9M).
Long Term Liabilities: 1RC's short term assets (£32.1M) exceed its long term liabilities (£12.0M).
Debt to Equity History and Analysis
Debt Level: 1RC's net debt to equity ratio (9.3%) is considered satisfactory .
Reducing Debt: 1RC's debt to equity ratio has increased from 1% to 30% over the past 5 years.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1RC has sufficient cash runway for 5 months based on last reported free cash flow , but has since raised additional capital.
Forecast Cash Runway: 1RC is forecast to have sufficient cash runway for 8 months based on free cash flow estimates , but has since raised additional capital.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}